Goserelin is a synthetic analog of luteinizing hormone-releasing hormone used to treat breast cancer and prostate cancer by reducing secretion of gonadotropins from the pituitary. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells.
- Mechanism
- Curator reviewed
Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
- Primary indication
- Goserelin is indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Palliative treatment of advanced carcinoma of the prostate The management of endometriosis Use as an endometrial-thinning...Curator reviewed · 7 structured indications
- Formula / weight
- C59H84N18O14 · 1269.4105 g/mol (avg)
- First approval
- Canada, 2017 · United States, 2003
- Code names
- ICI-118630
- Brand names
Resolves to
BLCLNMBMMGCOAS-URPVMXJPSA-NSMILESCC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Goserelin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account